Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Shanghai Shenqi Pharmaceutical Investment Management Co LT-Debt-to-Total-Asset?

Shanghai Shenqi Pharmaceutical Investment Management Co SHSE:600613 +0.43% 53 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates SHSE:600613 with a GF Score™ of 53/100 and a GF Value™ of ¥5.43 (Modestly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shanghai Shenqi Pharmaceutical Investment Management Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Shanghai Shenqi Pharmaceutical Investment Management Co's long-term debt to total assets ratio declined from Mar. 2025 (0.04) to Mar. 2026 (0.00). It may suggest that Shanghai Shenqi Pharmaceutical Investment Management Co is progressively becoming less dependent on debt to grow their business.

Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shanghai Shenqi Pharmaceutical Investment Management Co LT-Debt-to-Total-Asset Related Terms

Shanghai Shenqi Pharmaceutical Investment Management Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Shanghai Shenqi Pharmaceutical Investment Management Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Shenqi Pharmaceutical Investment Management Co LT-Debt-to-Total-Asset Chart

Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.07

0.06

0.05

0.03

Shanghai Shenqi Pharmaceutical Investment Management Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.03	0.00

53GF Score

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd SHSE:600613

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Shanghai Shenqi Pharmaceutical Investment Management Co LT-Debt-to-Total-Asset Calculation

Shanghai Shenqi Pharmaceutical Investment Management Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	100.909	/	3145.125
	=	0.03

Shanghai Shenqi Pharmaceutical Investment Management Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	11.509	/	3044.359
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.

Is Shanghai Shenqi Pharmaceutical Investment Management Co's LT-Debt-to-Total-Asset too high?

Shanghai Shenqi Pharmaceutical Investment Management Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Shanghai Shenqi Pharmaceutical Investment Management Co's LT-Debt-to-Total-Asset compare to LLY and JNJ?

Shanghai Shenqi Pharmaceutical Investment Management Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.43, compared to a current price of ¥4.63 — trading 14.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued. The current stock price of ¥4.63 is trading 14.7% below its estimated GF Value™ of ¥5.43. GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.

Key valuation signals for SHSE:600613:

LT-Debt-to-Total-Asset: 0.00
GF Value™: ¥5.43 vs. price of ¥4.63 (14.7% below fair value)
GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Shenqi Pharmaceutical Investment Management Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SHSE:600671 SZSE:000705 SZSE:000952 BJSE:920009 SZSE:001367 SZSE:002198 SZSE:301507 SZSE:300006 SZSE:301281 SZSE:000411 LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B AMGN GILD

Other Exchanges 900904:China

Address 128 Weihai Road, Room 613, Changfa Building, Shanghai, CHN, 200003

Website http://www.gzsq.com

Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is mainly engaged in pharmaceutical production and distribution in China.

53GF Score

Get the complete analysis for SHSE:600613

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.63

Price

¥5.43

GF Value

View SHSE:600613 Analysis

See LT-Debt-to-Total-Asset data for all stocks →